CytomX Therapeutics (CTMX) Net Cash Flow (2014 - 2026)

CytomX Therapeutics has reported Net Cash Flow for 13 years, with the latest figure at $16.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 69.17% year-over-year to $16.2 million; the trailing twelve-month figure through Mar 2026 stood at -$18.3 million (down 258.52% YoY), and the FY2025 full-year result was -$24.9 million, down 218.55% from the prior year.
• Net Cash Flow for Q1 2026 stood at $16.2 million, up from -$21.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $98.6 million in Q4 2022, with the low at -$137.3 million in Q1 2023.
• Historically, Net Cash Flow has averaged -$10.4 million across 5 years, with a median of -$2.6 million in 2024.
• Annual changes were most pronounced in 2024 — Net Cash Flow jumped 498.98% — and 2025, when it slumped 732.77%.
• CytomX Therapeutics' Net Cash Flow stood at $98.6 million in 2022, then sank by 108.98% to -$8.9 million in 2023, then soared by 71.49% to -$2.5 million in 2024, then tumbled by 732.77% to -$21.0 million in 2025, then surged by 176.89% to $16.2 million in 2026.
• The last three Net Cash Flow figures came in at $16.2 million (Q1 2026), -$21.0 million (Q4 2025), and -$14.9 million (Q3 2025), per Business Quant data.